We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
Read MoreHide Full Article
Bayer (BAYRY - Free Report) announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor.
The drug is now fully approved in the United States for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that has spread or for those who are not eligible for surgery. The drug was approved for patients who did not have any satisfactory alternative treatment or whose disease progressed following treatment.
Please note that Vitrakvi was first granted accelerated approval by the FDA in November 2018.
More on BAYRY's Vitrakvi
The full FDA approval was based on the results of confirmatory trials that support Vitrakvi as a potential new standard of care treatment option for NTRK gene fusion-positive tumors in adult and pediatric patients.
Vitrakvi, a first-in-class oral TRK inhibitor, was exclusively designed to inhibit against the TRK family of proteins (TRKA, TRKB and TRKC).
Pooled efficacy results from three multicenter, open-label, single-arm clinical trials — LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431) — showed an overall response rate of 60% with a complete response rate of 24% and a partial response rate of 36%.
Bayer obtained the exclusive licensing rights for the global development and commercialization of Vitrakvi following the acquisition of Loxo Oncology by Eli Lilly and Company in February 2019.
Bayer Looks to Solidify Portfolio
2025 is likely to be another challenging year for this German pharma giant as it expects earnings to decline and sales to grow modestly. The uncertainty caused by ongoing Roundup litigation is also a major hangover on the stock.
Sales growth was encouraging in the Pharmaceutical division in 2024. New products, Nubeqa and Kerendia, retained their impressive momentum and offset the negative impact of a decline in Xarelto sales. The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth.
Successful development of additional drugs is imperative for Bayer amid multiple challenges. BAYRY expects to launch two new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain type of heart disease.
Shares of BAYRY have surged 15.4% year to date against the industry’s decline of 8.2%.
Image Source: Zacks Investment Research
The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired clinical-stage biopharmaceutical company Vividion Therapeutics to expand into precision small-molecule therapeutics, primarily in oncology and immunology.
BAYRY has expanded its pipeline in new modalities of cell therapy, through the acquisition of BlueRock, and gene therapy, through the acquisition of AskBio.
The company recently announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.
Suzhou Puhe BioPharma is focused on the research and development of innovative small-molecule precision therapeutics.
In the past 60 days, estimates for Amicus’ earnings per share (EPS) have increased from 43 cents to 52 cents for 2025. During the same time frame, EPS estimates for 2026 have increased from 71 cents to 79 cents.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 45.42%.
ANI Pharmaceuticals
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $5.54 to $6.34 for 2025. During the same period, EPS estimates for 2026 have increased from $6.90 to $7.13. Year to date, shares of ANIP have rallied 14%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
Bayer (BAYRY - Free Report) announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK inhibitor.
The drug is now fully approved in the United States for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that has spread or for those who are not eligible for surgery. The drug was approved for patients who did not have any satisfactory alternative treatment or whose disease progressed following treatment.
Please note that Vitrakvi was first granted accelerated approval by the FDA in November 2018.
More on BAYRY's Vitrakvi
The full FDA approval was based on the results of confirmatory trials that support Vitrakvi as a potential new standard of care treatment option for NTRK gene fusion-positive tumors in adult and pediatric patients.
Vitrakvi, a first-in-class oral TRK inhibitor, was exclusively designed to inhibit against the TRK family of proteins (TRKA, TRKB and TRKC).
Pooled efficacy results from three multicenter, open-label, single-arm clinical trials — LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431) — showed an overall response rate of 60% with a complete response rate of 24% and a partial response rate of 36%.
Bayer obtained the exclusive licensing rights for the global development and commercialization of Vitrakvi following the acquisition of Loxo Oncology by Eli Lilly and Company in February 2019.
Bayer Looks to Solidify Portfolio
2025 is likely to be another challenging year for this German pharma giant as it expects earnings to decline and sales to grow modestly. The uncertainty caused by ongoing Roundup litigation is also a major hangover on the stock.
Sales growth was encouraging in the Pharmaceutical division in 2024. New products, Nubeqa and Kerendia, retained their impressive momentum and offset the negative impact of a decline in Xarelto sales. The company is working to expand the labels of its key drugs, Nubeqa and Kerendia, which should boost growth.
Successful development of additional drugs is imperative for Bayer amid multiple challenges. BAYRY expects to launch two new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain type of heart disease.
Shares of BAYRY have surged 15.4% year to date against the industry’s decline of 8.2%.
Image Source: Zacks Investment Research
The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired clinical-stage biopharmaceutical company Vividion Therapeutics to expand into precision small-molecule therapeutics, primarily in oncology and immunology.
BAYRY has expanded its pipeline in new modalities of cell therapy, through the acquisition of BlueRock, and gene therapy, through the acquisition of AskBio.
The company recently announced a licensing agreement with Suzhou Puhe BioPharma Co., a clinical-stage biotechnology company.
Suzhou Puhe BioPharma is focused on the research and development of innovative small-molecule precision therapeutics.
Bayer’s Zacks Rank & Other Key Picks
BAYRY currently carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the pharma/biotech sector are Amicus Therapeutics, Inc. (FOLD - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amicus Therapeutics
In the past 60 days, estimates for Amicus’ earnings per share (EPS) have increased from 43 cents to 52 cents for 2025. During the same time frame, EPS estimates for 2026 have increased from 71 cents to 79 cents.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 45.42%.
ANI Pharmaceuticals
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $5.54 to $6.34 for 2025. During the same period, EPS estimates for 2026 have increased from $6.90 to $7.13. Year to date, shares of ANIP have rallied 14%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.